Crown Bioscience Closes $28.8M Series C Financing Round
Crown Bioscience Inc. closed a Series C financing round at $28.8 million. OrbiMed Advisors Caduceus Asia Partners Fund, Argonaut Private Equity, the CID Group, IBT and CDIB Capital Investment led the round. Existing shareholders Qiming Venture Partners and CRCI also participated.Crown Bioscience plans to use proceeds to expand services in integrated cancer drug discovery and translational oncology, as well as to fund new initiatives in other therapeutic areas. Crown Bioscience is a Santa Clara, Calif.-based company involved in oncology research and development partnership and services.
4 May 2011•5 mins read
